NCT04546074 - Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions

Melanoma

Interventions

DRUG

Pembrolizumab and Imatinib mesylate

"In Phase Ib study:~Level 1: Imatinib mesylate 200mg QD + Pembrolizumab 200mg Q3W, Level 2: Imatinib mesylate 400mg QD + Pembrolizumab 200mg Q3W"

DRUG

Pembrolizumab and Imatinib mesylate

In Phase II study, eligible patients receive the dose determined in phase Ib cohort.

Trial Locations (1)

RECRUITING

Keio University Hospital, Shinjuku